Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Medimetriks Pharmaceuticals has commenced operations. The newly-formed company will develop, license and commercialize innovative prescription products for the dermatology and podiatry marketplaces.
Subscribe to our email newsletter
The company is aggressively pursuing licensing opportunities, company and product acquisitions and initiating the development of a series of brands that will fill unmet needs in the marketplace. Medimetriks’s objective is to build a robust product portfolio and become a leading dermatology and podiatry specialty company.
Bradley Pharmaceuticals was acquired earlier in 2008 by Nycomed for approximately $350 million. Bradley Glassman, the former senior vice president of sales and marketing for Bradley, will serve as president and CEO of Medimetriks Pharmaceuticals, Brent Lenczycki as CFO and Alan Goldstein as executive vice president, business development. Daniel Glassman, the former president and CEO of Bradley, will serve as Medimetriks’s chairman of the board.
Mr Glassman said, “We will leverage our core expertise of identifying and delivering important and effective brands in the therapeutic markets that we know so well. In building the Bradley business, we developed long-standing relationships with leading physicians in both the dermatology and podiatry specialties.”